Lotus Pharmaceuticals has a myriad of drugs ready for market deployment with Chinese FDA approval. Pharmaceuticals continue to be the largest and most profitable business for Lotus. Cardiovascular drugs including VALSARTAN, which is used to control hypertension, is a commonly prescribed drug in China.
There are four divisions of Lotus which handle scientific research on new medicine, the production, wholesale and retail of medicine to treat chronic myeloid leukemia. With a total of twelve projects in clinical development, Lotus has a broad and innovative pipeline.
Lotus has the Chinese advantage. It is on the ground and up and running. It has its own drug stores.
The fundamental reality according to Chemical & Engineering News, March 2007, is China’s pharmaceutical industry is undergoing a major upgrade. Chinese who have spent decades living abroad are returning in large numbers to inject world-class practices into the country’s pharmaceutical business. This strong dose of talent is complemented by spirited government efforts to build up the R&D capabilities of universities and research institutes.
“I have confidence that, in the near future, we will have some drugs 100% made in China,” says Ningni Yu, the executive in charge of promoting pharmaceutical business activities in Shanghai’s Zhangjiang Hi-Tech Park. Yu is well-known among executives who are setting up R&D organizations in Shanghai as an effective matchmaker and troubleshooter.
“More and more companies are doing research here,” Yu says. Indeed, her problem nowadays is not attracting new companies but finding space for all the firms that want to conduct R&D in Zhangjiang.
There are about 60,000 Chinese “returnees” in Shanghai alone, Yu says. They are coming to the city with foreign degrees as well as valuable work experience. Many are scientists. In China, typically, the best and brightest strive to study science, not business or law as is common in Western countries, she says.
Lotus has a strong foundation in China. Chinese companies are typically favored over western companies. Lotus has a phenomenal pipeline and it is ready to launch major drugs. (Link here for the list.)
Source: Lotus Pharmaceuticals and Chemical and Engineering News, March 2007
Lotus Pharmaceuticals, Inc.
7900 Glades Road, Suite 420
Boca Raton, Florida 33434
Phone: (877) 801-0344
Fax: (954) 337-2204 Email: info@lotuseast.com
Disclosure: Pentony Enterprises LLC was compensated $10,000 directly from the company for profile coverage. Pentony Enterprises LLC is not a registered investment adviser or broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site are suitable or advisable for any person or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.
Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the company and its management. Such statements reflect management’s current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the Company’s ability to obtain additional financing and the demand for the Company’s products. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company’s expectations with regard to these forward-look ing statements or the occurrence of unanticipated events. Factors that may impact the Company’s success are more fully disclosed in the Company’s most recent public filings with the U.S. Securities and Exchange Commission (“SEC”).
StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (469) 252-3030. Web: StockGuru.com. Email: Publisher@stockguru.com.